ArticleInternational urology and nephrology2025
The global burden of chronic kidney disease due to glomerulonephritis: trends and predictions.
Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Exploring the global, regional, and Chinese disease burden of acute glomerulonephritis from 1990 to 2021 and future trends up to 2039 based on the 2021 Global Burden of Disease Database.International urology and nephrology · 2026Article
- Albuminuria or proteinuria in glomerular disease and CKD-which one to use?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026Article
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
- Pregnancy-associated dense deposit disease with neurological complications caused by Salmonella Typhi: A case report.Qatar medical journal · 2026Article
- Treatment outcomes and determinants of combined hemodialysis-hemoperfusion therapy in chronic glomerulonephritis.American journal of translational research · 2025Article
Corrections and comments
- Commented on by
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGlomerulonephritis (GN), one of the primary causes of chronic kidney disease (CKD), is gaining recognition as a major public health issue. This research sought to evaluate the worldwide impact of chronic kidney disease due to glomerulonephritis (GN-CKD) between 1990 and 2021 and to forecast trends up to 2036, leveraging data from the Global Burden of Disease (GBD) study.
methodsThe analysis of GN-CKD from 1990 to 2021 utilized GBD open data as a secondary dataset to examine global prevalence, deaths, disability-adjusted life years (DALYs), and age-standardized rates of GN-CKD, and the changing trends of these indicators were statistically analyzed. To assess the practical difference between each country/region and the frontier, we utilized the 2021 DALYs and Socio-Demographic Index (SDI). To assist healthcare institutions in formulating more effective public health policies, the age-standardized mortality and DALYs rate until 2036 were predicted using Bayesian age-period-cohort (BAPC) modeling techniques.
resultsThe global prevalence rate of GN-CKD, as indicated by the age-standardized prevalence rate (ASPR), grew 10.81% between 1990 and 2021, with a marginal average annual change of 0.04 (AAPC0.04, 0.03-0.05). Similarly, there was an increase of 15.84% in the age-standardized death rate (ASDR) for GN-CKD during this period, with an average annual trend of 0.50 (AAPC0.50, 0.41-0.59). Moreover, the age-standardized DALYs rate (ASYR) for GN-CKD observed an upward trend of 8.60% from 1990 to 2021, with a modest average annual change of 0.27 (AAPC0.27, 0.17-0.37). Our findings indicate that the impact of GN-CKD differs across gender, geographic areas, and socioeconomic statuses. Elevated fasting plasma glucose levels, high body-mass index (BMI), and elevated systolic blood pressure were the main contributors to deaths and disability-adjusted life years (DALYs). Fortunately, the burden of GN-CKD is expected to diminish by 2036.
conclusionsThe worldwide impact of GN-CKD has risen, with variations observed between genders and across SDI regions. Encouraging trends point toward a potential reduction in GN-CKD-related burden in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.